

June 7, 2017



## Heat Biologics to Present at the 2017 Marcum Microcap Conference

**DURHAM, NC / ACCESSWIRE / June 7, 2017 / [Heat Biologics, Inc.](#)** ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, today announced that Jeff Wolf, Heat's CEO, will be presenting at the [2017 Marcum MicroCap Conference](#) on Thursday, June 15<sup>th</sup> at 11:30 AM EST.

### **About Heat Biologics, Inc.**

Heat Biologics, Inc. (NASDAQ: HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient's immune system against cancer. Heat has generated highly specific T cell-stimulating therapeutic vaccine platform technologies, *ImPACT* and *ComPACT*. These technologies, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells (one of the human immune system's most potent weapons against cancer), reversal of tumor-induced immune suppression, and T cell co-stimulation to further enhance patients' immune response. Currently, Heat is conducting a Phase 2 trial with HS-110 (viagenpumatumucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC).

Most recently, Heat acquired two T cell costimulators through the acquisition of Pelican Therapeutics, a subsidiary to Heat focused on developing agonists to TNFRSF25, a highly differentiated and potentially best-in-class T cell costimulatory receptor. TNFRSF25 has shown great promise due to its preferential specificity for stimulating the production of "memory" CD8+ T cells, the strongest predictive biomarker of clinical benefit from cancer immunotherapy. T cell costimulatory therapy, when combined with checkpoint inhibitors and other treatments, could significantly improve clinical responses for a broader range of patients. Pelican has conducted extensive preclinical studies and completed humanization of its lead monoclonal antibody, PTX-25.

Heat's wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat's gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.

For more information, please visit [www.heatbio.com](http://www.heatbio.com).

### **Contact:**

For Investor Inquiries:  
David Waldman

919-240-7133

[Investorrelations@heatbio.com](mailto:Investorrelations@heatbio.com)

For Media Inquiries:

Deanne Eagle

Planet Communications

917-837-5866

[deanne@planetcommunications.nyc](mailto:deanne@planetcommunications.nyc)

**SOURCE:** Heat Biologics, Inc.